OTCMKTS:REMIRemedent Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Remedent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.16 0.00 (0.00 %) (As of 05/29/2020 03:07 PM ET) Add Compare Share Today's Range$0.16Now: $0.16▼$0.1650-Day Range$0.16MA: $0.17▼$0.1852-Week Range$0.10Now: $0.16▼$0.20VolumeN/AAverage Volume535 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABeta-0.27 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping. It also provides GlamSmile veneers, which are ultra-thin claddings attached to the front of the patient's teeth leaving the patient's healthy tooth structure intact. In addition, the company offers SmileMe Mirror, an integrated marketing concept for the dental practice, which enables dentists to offer smile consultation in approximately 10 minutes; SmileSketch, a simulation software to make a sketch of what the patient could look like; and various Treatment Pages to explain the benefits of certain treatments, as well as Condor, an intra-oral 3D scanner. It sells its products to dental professionals in approximately 30 countries, including Europe, Asia, Latin America, the Pacific Rim, the Middle East, and the United States through dealers, as well as directly to the consumers through its internal sales force and third party distributors. The company was founded in 1986 and is headquartered in Ghent, Belgium.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Remedent. Previous Next 2.3 Community Rank Outperform VotesRemedent has received 61 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRemedent has received 73 “underperform” votes. (Add your “underperform” vote.)Community SentimentRemedent has received 54.48% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Remedent and other stocks. Vote “Outperform” if you believe REMI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe REMI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRemedent does not currently pay a dividend.Dividend GrowthRemedent does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Remedent insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioRemedent has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.59 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:REMI Previous Symbol CUSIPN/A CIK1078037 Webwww.remedent.com Phone011-32-9241-5880Debt Debt-to-Equity Ratio0.02 Current Ratio0.28 Quick Ratio0.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.60 million Price / SalesN/A Cash Flow$0.11 per share Price / Cash Flow1.44 Book Value$0.27 per share Price / Book0.59Profitability EPS (Most Recent Fiscal Year)N/A Net Income$2.13 million Net Margins168.45% Return on Equity39.56% Return on Assets26.14%Miscellaneous Employees11 Outstanding SharesN/AMarket CapN/A Next Earnings Date5/29/2020 (Estimated) OptionableNot Optionable OTC:REMI Rates by TradingView Receive REMI News and Ratings via Email Sign-up to receive the latest news and ratings for REMI and its competitors with MarketBeat's FREE daily newsletter. Remedent (OTCMKTS:REMI) Frequently Asked Questions How has Remedent's stock been impacted by COVID-19 (Coronavirus)? Remedent's stock was trading at $0.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REMI shares have decreased by 15.8% and is now trading at $0.16. View which stocks have been most impacted by Coronavirus. When is Remedent's next earnings date? Remedent is scheduled to release its next quarterly earnings announcement on Friday, May 29th 2020. View our earnings forecast for Remedent. Has Remedent been receiving favorable news coverage? Press coverage about REMI stock has been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Remedent earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutRemedent. Who are some of Remedent's key competitors? Some companies that are related to Remedent include Straumann (SAUHF), DENTSPLY SIRONA (XRAY), Sartorius (SARTF), SmileDirectClub (SDC), Biomerica (BMRA) and BIOLASE (BIOL). View all competitors. What other stocks do shareholders of Remedent own? Based on aggregate information from My MarketBeat watchlists, some companies that other Remedent investors own include CoStar Group (CSGP), Enterprise Products Partners (EPD), Kellogg (K), MKS Instruments (MKSI), M&T Bank (MTB), Old Line Bancshares, Inc. (MD) (OLBK), Restoration Hardware (RH), AT&T (T), Taiwan Semiconductor Mfg. (TSM) and Visteon (VC). Who are Remedent's key executives? Remedent's management team includes the following people: Mr. Guy De Vreese, Chairman & CEO (Age 64)Mr. Philippe Van Acker, CFO, Chief Accounting Officer, Controller & Director (Age 54)Mr. Mark E. Sernatinger, Exec. Officer of United States OfficeMr. Scott G. Juhl, Exec. Officer of United States OfficeMr. Stacey J. Ammons, Exec. Officer of United States Office What is Remedent's stock symbol? Remedent trades on the OTCMKTS under the ticker symbol "REMI." How do I buy shares of Remedent? Shares of REMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Remedent's stock price today? One share of REMI stock can currently be purchased for approximately $0.16. What is Remedent's official website? The official website for Remedent is www.remedent.com. How can I contact Remedent? Remedent's mailing address is BELGIUM ZUIDERLAAN 1-3 BUS 8, GHENT C9, 9000. The company can be reached via phone at 011-32-9241-5880. This page was last updated on 5/29/2020 by MarketBeat.com Staff
